Veracyte Announces New Afirma Xpression Atlas Data on Medullary Thyroid Cancer to Be Presented at ENDO 2019

Veracyte, Inc. (Nasdaq: VCYT) announced today that new data derived from the Afirma Xpression Atlas, which help characterize the genomic underpinning of medullary thyroid cancer (MTC), will be presented at ENDO 2019, the Endocrine Society’s annual meeting. The findings on this rare--but aggressive--form of thyroid cancer will be presented in a guided poster presentation during the conference, which is taking place March 23-26 in New Orleans, La.

“The Afirma Xpression Atlas is enabling us to shed new light on the scope and scale of gene alterations found in medullary thyroid cancer,” said Giulia C. Kennedy, Ph.D., chief medical and scientific officer of Veracyte. “We believe that, in the emerging era of precision medicine, such information will be vital to advancing the diagnosis and treatment of this aggressive cancer and we look forward to sharing our findings at ENDO 2019.”

The following guided poster will be presented during the meeting:

Title:				The Genomic Landscape of Preoperative FNAs Positive for the Afirma GSC Medullary Thyroid Cancer Classifier
Presenter:				S.G. Waguespack, M.D., University of Texas MD Anderson Cancer Center, Houston, Texas
Date:				Monday, March 25, 1:00 – 3:00 PM CT
Location:				ENDOExpo, Ernest N. Morial Convention Center

About Afirma

The Afirma Genomic Sequencing Classifier (GSC) and Xpression Atlas provide physicians with a comprehensive solution for a complex landscape in thyroid nodule diagnosis. The Afirma GSC was developed with RNA whole-transcriptome sequencing and machine learning and helps identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to help patients avoid unnecessary diagnostic thyroid surgery. The Afirma Xpression Atlas provides physicians with genomic alteration content from the same fine needle aspiration samples that are used in Afirma GSC testing and may help physicians decide with greater confidence on the surgical or therapeutic pathway for their patients. The Afirma Xpression Atlas includes 761 DNA variants and 130 RNA fusion partners in over 500 genes that are associated with thyroid cancer.